109.8K XNAS Volume
XNAS 24 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Brendan P. Eckelman | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 May 2024 | 2,510 | 6,667 | - | - | Stock Option (right to buy) | |
| Brendan P. Eckelman | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 May 2024 | 2,500 | 26,667 | - | - | Stock Option (right to buy) | |
| Kelly D. Deck | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2024 | 17,624 | 0 | - | - | Stock Option (right to buy) | |
| Kelly D. Deck | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2024 | 2,087 | 0 | - | - | Stock Option (right to buy) | |
| D. Deck Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2024 | 416 | 9,167 | - | - | Stock Option (right to buy) | |
| D. Kelly Deck | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2024 | 625 | 21,250 | - | - | Stock Option (right to buy) | |
| Deck Kelly D. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2024 | 1,459 | 14,583 | - | - | Stock Option (right to buy) | |
| D. Deck Kelly | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2024 | 396 | 17,624 | - | - | Stock Option (right to buy) | |
| Kelly D. Deck | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2024 | 110 | 18,020 | - | - | Stock Option (right to buy) | |
| Kelly D. Deck | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2024 | 3,113 | 18,130 | - | - | Stock Option (right to buy) | |
| Kelly D. Deck | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2024 | 16,777 | 21,243 | - | - | Stock Option (right to buy) | |
| Kelly D. Deck | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2024 | 32,431 | 2,087 | - | - | Stock Option (right to buy) | |
| Brendan P. Eckelman | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2024 | 1,898 | 9,177 | - | - | Stock Option (right to buy) | |
| Kelly D. Deck | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2024 | 42,523 | 38,020 | - | - | Stock Option (right to buy) | |
| Brendan P. Eckelman | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2024 | 4,152 | 29,167 | - | - | Stock Option (right to buy) | |
| Brendan P. Eckelman | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2024 | 2,150 | 37,850 | - | - | Stock Option (right to buy) | |
| Brendan P. Eckelman | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2024 | 6,877 | 30,973 | - | - | Stock Option (right to buy) | |
| Brendan P. Eckelman | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2024 | 6,681 | 33,319 | - | - | Stock Option (right to buy) | |
| Brendan P. Eckelman | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2024 | 19,898 | 11,075 | - | - | Stock Option (right to buy) | |
| Kelly D. Deck | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2024 | 10,417 | 9,583 | - | - | Stock Option (right to buy) | |
| Kelly D. Deck | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2024 | 53,958 | 16,042 | - | - | Stock Option (right to buy) | |
| Kelly D. Deck | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2024 | 8,125 | 21,875 | - | - | Stock Option (right to buy) | |
| Kimberly J. Manhard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Jon Faiz Kayyem | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Kristiina Vuori | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 24.20 per share. | 01 Mar 2023 | 39,600 | 2,035,953 | - | 24.2 | 958,348 | Common Stock |
| Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 24.71 per share. | 01 Mar 2023 | 400 | 2,035,553 | - | 24.7 | 9,883 | Common Stock |
| Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.40 per share. | 01 Feb 2023 | 10,120 | 2,076,683 | - | 25.4 | 257,094 | Common Stock |
| Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.08 per share. | 01 Feb 2023 | 14,608 | 2,087,496 | - | 25.1 | 366,366 | Common Stock |
| Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 24.29 per share. | 01 Feb 2023 | 13,449 | 2,102,104 | - | 24.3 | 326,710 | Common Stock |
| Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.66 per share. | 01 Feb 2023 | 693 | 2,086,803 | - | 25.7 | 17,780 | Common Stock |
| Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.89 per share. | 01 Feb 2023 | 1,130 | 2,075,553 | - | 25.9 | 29,261 | Common Stock |
| Jon Faiz Kayyem | Director | Sale of securities on an exchange or to another person at price $ 25.26 per share. | 23 Jan 2023 | 9,500 | 3,224,301 | - | 25.3 | 239,999 | Common Stock |
| Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 24.36 per share. | 03 Jan 2023 | 8,598 | 2,124,742 | - | 24.4 | 209,426 | Common Stock |
| Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 23.41 per share. | 03 Jan 2023 | 22,213 | 2,133,340 | - | 23.4 | 520,051 | Common Stock |
| Brendan P. Eckelman | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 23.99 per share. | 03 Jan 2023 | 3,003 | 2,115,553 | - | 24.0 | 72,043 | Common Stock |
| Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 23.11 per share. | 03 Jan 2023 | 4,102 | 2,118,556 | - | 23.1 | 94,786 | Common Stock |
| Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.09 per share. | 03 Jan 2023 | 2,084 | 2,122,658 | - | 25.1 | 52,293 | Common Stock |
| Kelly D. Deck | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Jon Faiz Kayyem | Director | Sale of securities on an exchange or to another person at price $ 27.61 per share. | 21 Dec 2022 | 1,959 | 3,233,801 | - | 27.6 | 54,088 | Common Stock |
| Jon Faiz Kayyem | Director | Sale of securities on an exchange or to another person at price $ 26.87 per share. | 21 Dec 2022 | 7,541 | 3,235,760 | - | 26.9 | 202,591 | Common Stock |
| Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 26.83 per share. | 06 Dec 2022 | 20,927 | 2,174,626 | - | 26.8 | 561,572 | Common Stock |
| Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 27.57 per share. | 06 Dec 2022 | 17,681 | 2,156,945 | - | 27.6 | 487,493 | Common Stock |
| Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 28.46 per share. | 06 Dec 2022 | 1,392 | 2,155,553 | - | 28.5 | 39,617 | Common Stock |
| Jon Faiz Kayyem | Director | Sale of securities on an exchange or to another person at price $ 29.33 per share. | 21 Nov 2022 | 2,733 | 3,250,068 | - | 29.3 | 80,153 | Common Stock |
| Jon Faiz Kayyem | Director | Sale of securities on an exchange or to another person at price $ 30.12 per share. | 21 Nov 2022 | 6,767 | 3,243,301 | - | 30.1 | 203,819 | Common Stock |
| Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 33.90 per share. | 01 Nov 2022 | 12,349 | 2,195,553 | - | 33.9 | 418,641 | Common Stock |
| Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 33.33 per share. | 01 Nov 2022 | 27,651 | 2,207,902 | - | 33.3 | 921,746 | Common Stock |
| Jon Faiz Kayyem | Director | Sale of securities on an exchange or to another person at price $ 30.58 per share. | 21 Oct 2022 | 5,928 | 3,252,801 | - | 30.6 | 181,255 | Common Stock |
| Jon Faiz Kayyem | Director | Sale of securities on an exchange or to another person at price $ 29.39 per share. | 21 Oct 2022 | 3,572 | 3,258,729 | - | 29.4 | 104,977 | Common Stock |
| Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 24.67 per share. | 04 Oct 2022 | 1,448 | 2,274,105 | - | 24.7 | 35,720 | Common Stock |
| Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 26.06 per share. | 04 Oct 2022 | 6,207 | 2,267,898 | - | 26.1 | 161,763 | Common Stock |
| Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 26.78 per share. | 04 Oct 2022 | 11,136 | 2,256,762 | - | 26.8 | 298,182 | Common Stock |
| Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 27.76 per share. | 04 Oct 2022 | 4,262 | 2,252,500 | - | 27.8 | 118,299 | Common Stock |
| Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 28.97 per share. | 04 Oct 2022 | 5,954 | 2,246,546 | - | 29.0 | 172,495 | Common Stock |
| Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 29.68 per share. | 04 Oct 2022 | 10,893 | 2,235,653 | - | 29.7 | 323,302 | Common Stock |
| Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 30.52 per share. | 04 Oct 2022 | 100 | 2,235,553 | - | 30.5 | 3,052 | Common Stock |
| Brendan P. Eckelman | Chief Scientific Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Sep 2022 | 80,000 | 160,000 | - | 0 | Common Stock | |
| Brendan P. Eckelman | Chief Scientific Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Sep 2022 | 160,000 | 2,275,553 | - | 0 | Common Stock | |
| Brendan P. Eckelman | Chief Scientific Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 13 Sep 2022 | 80,000 | 160,000 | - | 0 | Common Stock | |
| Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 14.86 per share. | 06 Sep 2022 | 37,507 | 2,438,046 | - | 14.9 | 557,241 | Common Stock |
| Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 15.66 per share. | 06 Sep 2022 | 2,493 | 2,435,553 | - | 15.7 | 39,032 | Common Stock |
| Jon Faiz Kayyem | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 24 Aug 2022 | 11,900 | 3,262,301 | - | 0 | Common Stock | |
| Jon Faiz Kayyem | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 05 Aug 2022 | 3,400 | 3,274,201 | - | 0 | Common Stock | |
| Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 17.70 per share. | 02 Aug 2022 | 24,500 | 2,491,053 | - | 17.7 | 433,626 | Common Stock |
| Jon Faiz Kayyem | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 02 Aug 2022 | 118,500 | 3,277,601 | - | 0 | Common Stock | |
| Jon Faiz Kayyem | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 02 Aug 2022 | 25,000 | 25,000 | - | 0 | Common Stock | |
| Jon Faiz Kayyem | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 02 Aug 2022 | 25,000 | 25,000 | - | 0 | Common Stock | |
| Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 18.47 per share. | 02 Aug 2022 | 15,500 | 2,475,553 | - | 18.5 | 286,209 | Common Stock |
| Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 17.17 per share. | 07 Jul 2022 | 40,000 | 2,515,553 | - | 17.2 | 686,800 | Common Stock |
| Kimberly J. Manhard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 15,000 | 50,759 | - | - | Stock Option (right to buy) | |
| Kristiina Vuori | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 15,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Jon Faiz Kayyem | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 15,000 | 47,259 | - | - | Stock Option (right to buy) | |
| Brendan P. Eckelman | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.04 per share. | 05 Apr 2022 | 400 | 2,555,553 | - | 25.0 | 10,016 | Common Stock |
| Kelly D. Deck | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Kristiina Vuori | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2021 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Jon Faiz Kayyem | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 15,000 | 32,259 | - | - | Stock Option (right to buy) | |
| Kimberly J. Manhard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2021 | 15,000 | 35,759 | - | - | Stock Option (right to buy) | |
| Brendan P. Eckelman | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 19.02 per share. | 24 Mar 2021 | 17,000 | 2,555,953 | - | 19.0 | 323,340 | Common Stock |
| Klaus W. Wagner | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.29 per share. | 16 Feb 2021 | 19,559 | 215,150 | - | 25.3 | 494,647 | Common Stock |
| Klaus W. Wagner | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 24.32 per share. | 16 Feb 2021 | 156,474 | 234,709 | - | 24.3 | 3,805,448 | Common Stock |
| Brendan P. Eckelman | Director, Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.90 per share. | 16 Feb 2021 | 17,000 | 2,572,953 | - | 25.9 | 440,300 | Common Stock |
| Kelly D. Deck | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 70,000 | 70,000 | - | - | Stock Option (right to buy) | |
| Klaus W. Wagner | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 120,000 | 120,000 | - | - | Stock Option (right to buy) | |
| Brendan P. Eckelman | Director, Chief Scientific Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 15 Jan 2021 | 160,000 | 2,589,953 | - | 0 | Common Stock | |
| Brendan P. Eckelman | Director, Chief Scientific Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 15 Jan 2021 | 80,000 | 80,000 | - | 0 | Common Stock | |
| Brendan P. Eckelman | Director, Chief Scientific Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 15 Jan 2021 | 80,000 | 80,000 | - | 0 | Common Stock | |
| Brendan P. Eckelman | Director, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Kimberly J. Manhard | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Aug 2020 | 17,259 | 17,259 | - | - | Common Stock |